Craig Barratt Sells 2,193 Shares of Intuitive Surgical (NASDAQ:ISRG) Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Craig Barratt sold 2,193 shares of the stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $548.01, for a total value of $1,201,785.93. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Intuitive Surgical Trading Down 1.1%

Shares of Intuitive Surgical stock opened at $545.39 on Wednesday. The business’s 50 day simple moving average is $460.82 and its 200-day simple moving average is $497.70. The stock has a market capitalization of $195.51 billion, a price-to-earnings ratio of 72.14, a PEG ratio of 5.07 and a beta of 1.61. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.41. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.The business had revenue of $2.51 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the prior year, the firm earned $1.84 EPS. The business’s quarterly revenue was up 22.9% on a year-over-year basis. Sell-side analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of recent analyst reports. Sanford C. Bernstein reissued an “outperform” rating and issued a $685.00 price objective on shares of Intuitive Surgical in a report on Tuesday, October 21st. Raymond James Financial set a $603.00 price objective on Intuitive Surgical and gave the stock an “outperform” rating in a report on Wednesday, October 22nd. Mizuho set a $575.00 price objective on Intuitive Surgical in a report on Wednesday, October 22nd. Weiss Ratings reissued a “hold (c+)” rating on shares of Intuitive Surgical in a report on Wednesday, October 8th. Finally, BTIG Research increased their price objective on Intuitive Surgical from $529.00 to $589.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and an average target price of $608.92.

Hedge Funds Weigh In On Intuitive Surgical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ISRG. Chilton Capital Management LLC boosted its stake in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 43 shares in the last quarter. Tobam boosted its stake in shares of Intuitive Surgical by 666.7% during the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 40 shares in the last quarter. Elite Financial Inc. bought a new stake in shares of Intuitive Surgical during the 1st quarter worth $26,000. Kilter Group LLC bought a new stake in shares of Intuitive Surgical during the 2nd quarter worth $27,000. Finally, LFA Lugano Financial Advisors SA bought a new stake in shares of Intuitive Surgical during the 1st quarter worth $30,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.